Healthcare German Community

My main narrative for FRE: What former CEO Mark Schneider blow up to an inefficient giant, will now be cut down by actual CEO Michael Sen and trimmed on efficiency from formally 4 segments FMC (dialyses), Helios (private hospitals), Kabi(Generic & Infusions), Vamed (Projects & Digitalization) only 2 remain: Helios, Kabi, the other will be sold, and the intakes will help to restructure the financial situation under Mark Schneider the Spanish hospitals were acquired, this was a good deal: privat hospital runs well in Spain, because of their good reputation wealthy Latin Americans travel for medical treatments to Spain I focus also on: More equity than debt. Ratio is at 62% (debt/equity).Read more

Siemens Healthineers keeps selling more imaging and therapy equipment, but tariffs, currency swings, and heavy spending on new machines could stop those gains from turning into much better profits. The big question is whether new AI features and long-term hospital partnerships become widely used fast enough to change the story.Read more

Ottobock could benefit as more people need help regaining movement and as insurers and health systems make it easier to access advanced braces, prosthetics, and neuro rehab devices. The catch is that some recent demand may fade and the company’s growth plan depends on smooth reimbursement rollouts and successful deal-making.Read more

Medios is trying to grow its specialty drug business beyond Germany through deal-making and a push into more customized therapies, but combining new businesses and meeting stricter rules could take longer than hoped. Read on for why aging populations may boost demand while tighter healthcare budgets and new digital competitors could still squeeze growth.Read more

Carl Zeiss Meditec sells eye-care equipment worldwide, but shifting rules, tighter healthcare budgets, and trade frictions could make hospitals slower to buy and squeeze what the company earns on each sale. At the same time, cheaper rivals and new digital tools threaten its premium products—while recurring service revenue, new launches, and targeted deals may help steady the business.Read more

Fresenius Medical Care could ride a wave of older patients and rising chronic disease, while making it easier for people to start and stay on treatment. But new types of kidney care, changing payment rules, and uneven performance in newer business lines could reshape how dependable its core dialysis business really is.Read more

Siemens Healthineers is built around the tools hospitals use to find and treat the biggest long-term health problems, and new imaging and diagnostic upgrades could help it win more high-value projects and service work. The bigger question is whether pressure in China and other outside shocks keep a key part of the business from bouncing back.Read more

Carl Zeiss Meditec is leaning harder into recurring revenue from eye procedures and digital tools, which could make its results steadier as global demand for eye care rises. But price pressure, fast-moving tech rivals, and trade frictions could squeeze profits if the company can’t keep innovating and protect its premium positioning.Read more

Siemens Healthineers is leaning into smarter imaging and AI tools, plus deeper partnerships with hospitals, to turn more of its business into steadier, repeatable sales as healthcare goes digital. The big question is whether tariffs, tougher pricing in China, and currency swings undermine those gains just as global demand for diagnostics rises with aging populations and chronic disease.Read more